[go: up one dir, main page]

NO20081725L - Bicykliske derivater som modulatorer for spenningsaktiverte ione-kanaler - Google Patents

Bicykliske derivater som modulatorer for spenningsaktiverte ione-kanaler

Info

Publication number
NO20081725L
NO20081725L NO20081725A NO20081725A NO20081725L NO 20081725 L NO20081725 L NO 20081725L NO 20081725 A NO20081725 A NO 20081725A NO 20081725 A NO20081725 A NO 20081725A NO 20081725 L NO20081725 L NO 20081725L
Authority
NO
Norway
Prior art keywords
modulators
voltage
ion channels
bicyclic derivatives
activated ion
Prior art date
Application number
NO20081725A
Other languages
English (en)
Norwegian (no)
Inventor
Nicole Zimmermann
Timothy Neubert
Esther Martinborough
Andreas Termin
Artis Kawatkar
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of NO20081725L publication Critical patent/NO20081725L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20081725A 2005-09-09 2008-04-09 Bicykliske derivater som modulatorer for spenningsaktiverte ione-kanaler NO20081725L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71598005P 2005-09-09 2005-09-09
PCT/US2006/034857 WO2007030618A2 (fr) 2005-09-09 2006-09-08 Derives bicycliques constituant des modulateurs des canaux ioniques sensibles au voltage

Publications (1)

Publication Number Publication Date
NO20081725L true NO20081725L (no) 2008-06-09

Family

ID=37686027

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081725A NO20081725L (no) 2005-09-09 2008-04-09 Bicykliske derivater som modulatorer for spenningsaktiverte ione-kanaler

Country Status (14)

Country Link
US (4) US7855220B2 (fr)
EP (1) EP1928871A2 (fr)
JP (1) JP2009507851A (fr)
KR (1) KR20080044910A (fr)
CN (1) CN101300253B (fr)
AU (1) AU2006287480B2 (fr)
CA (1) CA2622076A1 (fr)
IL (1) IL190017A0 (fr)
MX (1) MX2008003337A (fr)
NO (1) NO20081725L (fr)
NZ (1) NZ567132A (fr)
RU (1) RU2008113836A (fr)
WO (1) WO2007030618A2 (fr)
ZA (1) ZA200802977B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491827B2 (en) * 2002-12-23 2009-02-17 Millennium Pharmaceuticals, Inc. Aryl sulfonamides useful as inhibitors of chemokine receptor activity
US7615563B2 (en) * 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
WO2006122014A2 (fr) 2005-05-10 2006-11-16 Vertex Pharmaceuticals Incorporated Derives bicycliques utilises en tant que modulateurs de canaux ioniques
ZA200710332B (en) * 2005-05-16 2009-03-25 Vertex Pharma Bicyclic derivatives as modulators of ion channels
WO2007030618A2 (fr) * 2005-09-09 2007-03-15 Vertex Pharmaceuticals Incorporated Derives bicycliques constituant des modulateurs des canaux ioniques sensibles au voltage
JP2009512717A (ja) * 2005-10-21 2009-03-26 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルを調節するための誘導体
TW200740803A (en) 2005-12-21 2007-11-01 Vertex Pharma Heterocyclic derivatives as modulators of ion channels
AU2008256937A1 (en) 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US7994174B2 (en) * 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
AU2008321137A1 (en) * 2007-11-13 2009-05-22 Vertex Pharmaceuticals Incorporated 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain
US8097636B2 (en) * 2007-11-13 2012-01-17 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
WO2009133641A1 (fr) * 2008-04-30 2009-11-05 シャープ株式会社 Dispositif d'éclairage et dispositif d'affichage
EP2307412A2 (fr) * 2008-07-01 2011-04-13 Vertex Pharmaceuticals Incorporated Dérivés hétérocycliques en tant que modulateurs des canaux ioniques
ES2420854T3 (es) * 2008-07-02 2013-08-27 F. Hoffmann-La Roche Ag Nuevas fenilpirazinonas como inhibidores de quinasas
US20110136842A1 (en) * 2008-08-06 2011-06-09 Duffy Joseph L Substituted Dihydroisoquinolinone and Isoquinolinedione Derivatives as Calcium Channel Blockers
AR094667A1 (es) 2013-01-31 2015-08-19 Vertex Pharma Piridonamidas como moduladores de canales de sodio
AU2019301628C1 (en) 2018-07-09 2025-02-06 Lieber Institute, Inc. Pyridine carboxamide compounds for inhibiting NaV1.8
JP7623275B2 (ja) 2018-07-09 2025-01-28 リーバー インスティチュート インコーポレイテッド ＮａＶ１．８を阻害するピリダジン化合物
WO2021136238A1 (fr) * 2019-12-30 2021-07-08 武汉朗来科技发展有限公司 Composé cyclique fusionné et son utilisation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
TWI234557B (en) * 1999-05-26 2005-06-21 Telik Inc Novel naphthalene ureas as glucose uptake enhancers
JP2003055209A (ja) * 2001-07-31 2003-02-26 Bayer Ag フェニルナフチル尿素誘導体
WO2003097586A1 (fr) * 2002-05-17 2003-11-27 Janssen Pharmaceutica N.V. Modulateurs de l'uree derives de l'aminotetraline du recepteur vanilloide vr1
US7491827B2 (en) * 2002-12-23 2009-02-17 Millennium Pharmaceuticals, Inc. Aryl sulfonamides useful as inhibitors of chemokine receptor activity
US7615563B2 (en) 2003-08-08 2009-11-10 Gonzalez Iii Jesus E Compositions useful as inhibitors of voltage-gated sodium channels
NZ579370A (en) * 2003-08-08 2011-06-30 Vertex Pharma Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain
WO2006122014A2 (fr) * 2005-05-10 2006-11-16 Vertex Pharmaceuticals Incorporated Derives bicycliques utilises en tant que modulateurs de canaux ioniques
ZA200710332B (en) * 2005-05-16 2009-03-25 Vertex Pharma Bicyclic derivatives as modulators of ion channels
WO2006133459A1 (fr) * 2005-06-09 2006-12-14 Vertex Pharmaceuticals Incorporated Derives d'indane comme modulateurs de canaux ioniques
WO2007030618A2 (fr) 2005-09-09 2007-03-15 Vertex Pharmaceuticals Incorporated Derives bicycliques constituant des modulateurs des canaux ioniques sensibles au voltage
JP2009511599A (ja) * 2005-10-12 2009-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体
JP2009512717A (ja) 2005-10-21 2009-03-26 バーテックス ファーマシューティカルズ インコーポレイテッド イオンチャネルを調節するための誘導体
TW200740803A (en) 2005-12-21 2007-11-01 Vertex Pharma Heterocyclic derivatives as modulators of ion channels
US8293450B2 (en) * 2006-11-28 2012-10-23 Hewlett-Packard Development Company, L.P. Laser imaging coating and methods for imaging
AU2008256937A1 (en) * 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
US7994174B2 (en) 2007-09-19 2011-08-09 Vertex Pharmaceuticals Incorporated Pyridyl sulfonamides as modulators of ion channels
US8097636B2 (en) 2007-11-13 2012-01-17 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
AU2008321137A1 (en) 2007-11-13 2009-05-22 Vertex Pharmaceuticals Incorporated 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazol-2-yl)benzenesulfonamide derivati ves and related compounds as modulators of ion channels for the treatment of pain
EP2307412A2 (fr) 2008-07-01 2011-04-13 Vertex Pharmaceuticals Incorporated Dérivés hétérocycliques en tant que modulateurs des canaux ioniques

Also Published As

Publication number Publication date
AU2006287480A8 (en) 2012-02-02
IL190017A0 (en) 2008-08-07
US8492403B2 (en) 2013-07-23
US20130131109A1 (en) 2013-05-23
US8236829B2 (en) 2012-08-07
MX2008003337A (es) 2008-09-26
US20070203130A1 (en) 2007-08-30
US7855220B2 (en) 2010-12-21
KR20080044910A (ko) 2008-05-21
CN101300253B (zh) 2012-08-22
RU2008113836A (ru) 2009-10-20
NZ567132A (en) 2011-12-22
EP1928871A2 (fr) 2008-06-11
JP2009507851A (ja) 2009-02-26
US20120308606A1 (en) 2012-12-06
CA2622076A1 (fr) 2007-03-15
AU2006287480B2 (en) 2012-07-05
ZA200802977B (en) 2009-08-26
US20110112156A1 (en) 2011-05-12
CN101300253A (zh) 2008-11-05
US8357702B2 (en) 2013-01-22
AU2006287480A1 (en) 2007-03-15
WO2007030618A2 (fr) 2007-03-15
WO2007030618A3 (fr) 2007-05-31

Similar Documents

Publication Publication Date Title
NO20081725L (no) Bicykliske derivater som modulatorer for spenningsaktiverte ione-kanaler
NO20082165L (no) Bifenylderivater som modulatorer av spenningsstyrte ionekanaler
NO20076306L (no) Bicykliske derivater som modulatorer av ionekanaler
JO2778B1 (en) Certain Compounds, Compositions and Methods
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
DK2089369T3 (da) 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
CO6361927A2 (es) Quinazolinas para inhibicion de pdk1
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
ECSP088823A (es) Quinazolinas para la inhibición de pdk1
WO2008147797A3 (fr) Modulateurs de canal ionique et leurs procédés d'utilisation
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
NO20090313L (no) Derivater og analoger av N-etylkinoloner og N-etylazakinoloner
CR20140422A (es) Composiciones de enzima digestiva estable
CR20110103A (es) Heteroarilos sustituidos
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
HN2008000179A (es) Compuestos triciclicos,composiciones y procedimientos
ECSP10010722A (es) Compuestos orgánicos
HN2010001761A (es) Derivados de azetidina y ciclobutano como inhibidores de jak
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
NO20090157L (no) Tienpyrimidiner anvendelige som modulatorer av ionekanaler
DK1682530T3 (da) Pyrrolsubstituerede indoler som inhibitorer af PAI-1
ECSP088749A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
NO20082746L (no) Kinazoliner anvendelige som modulatorer for spenningsstyrte ionekanaler

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application